{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:19:13Z","timestamp":1790302753840,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-0998-4","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T08:02:55Z","timestamp":1548057775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["SMArtCARE\u00a0-\u00a0A platform to collect real-life outcome data of patients with spinal muscular atrophy"],"prefix":"10.1186","volume":"14","author":[{"given":"Astrid","family":"Pechmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Bernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Schachtrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schorling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Schwersenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Tassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie C.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns","family":"Lochm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"998_CR1","doi-asserted-by":"publisher","unstructured":"Verhaart IEC, Robertson A, Leary R, McMacken G, K\u00f6nig K, Kirschner J, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264:1465\u201373. \n                    https:\/\/doi.org\/10.1007\/s00415-017-8549-1\n                    \n                  .","DOI":"10.1007\/s00415-017-8549-1"},{"key":"998_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83:810\u20137. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000000741\n                    \n                  .","journal-title":"Neurology"},{"key":"998_CR3","doi-asserted-by":"publisher","unstructured":"Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, de VDC, Kaufmann P. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69:1931\u20136. \n                    https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004\n                    \n                  .","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"998_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197\u2013207. \n                    https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004\n                    \n                  .","journal-title":"Neuromuscul Disord"},{"key":"998_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103\u201315. \n                    https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005\n                    \n                  .","journal-title":"Neuromuscul Disord"},{"key":"998_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1706198\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"998_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","volume":"16","author":"E Bertini","year":"2017","unstructured":"Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:513\u201322. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(17)30085-6\n                    \n                  .","journal-title":"Lancet Neurol"},{"key":"998_CR8","doi-asserted-by":"publisher","unstructured":"Parente V, Corti S. Advances in spinal muscular atrophy therapeutics. Ther Adv Neurol Disord. 2018;11:1756285618754501. \n                    https:\/\/doi.org\/10.1177\/1756285618754501\n                    \n                  .","DOI":"10.1177\/1756285618754501"},{"key":"998_CR9","doi-asserted-by":"publisher","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625\u201335. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1710504\n                    \n                  .","DOI":"10.1056\/NEJMoa1710504"},{"key":"998_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1702752\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"998_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JND-180315","volume":"5","author":"A Pechmann","year":"2018","unstructured":"Pechmann A, Langer T, Schorling D, Stein S, Vogt S, Schara U, et al. Evaluation of children with SMA type 1 under treatment with Nusinersen within the expanded access program in Germany. J Neuromuscul Dis. 2018;5:135\u201343. \n                    https:\/\/doi.org\/10.3233\/JND-180315\n                    \n                  .","journal-title":"J Neuromuscul Dis"},{"key":"998_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0022-3476(99)70016-8","volume":"135","author":"L Haataja","year":"1999","unstructured":"Haataja L, Mercuri E, Regev R, Cowan F, Rutherford M, Dubowitz V, Dubowitz L. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatr. 1999;135:153\u201361.","journal-title":"J Pediatr"},{"key":"998_CR13","doi-asserted-by":"publisher","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, et al. The Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20:155\u201361. \n                    https:\/\/doi.org\/10.1016\/j.nmd.2009.11.014\n                    \n                  .","DOI":"10.1016\/j.nmd.2009.11.014"},{"key":"998_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","volume":"7","author":"M Main","year":"2003","unstructured":"Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7:155\u20139.","journal-title":"Eur J Paediatr Neurol"},{"key":"998_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55:869\u201374. \n                    https:\/\/doi.org\/10.1002\/mus.25430\n                    \n                  .","journal-title":"Muscle Nerve"},{"key":"998_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54:836\u201342. \n                    https:\/\/doi.org\/10.1002\/mus.25120\n                    \n                  .","journal-title":"Muscle Nerve"},{"key":"998_CR17","first-page":"13","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169:13\u201321.","journal-title":"BDNF ALS Study Group (Phase III) J Neurol Sci"},{"key":"998_CR18","volume-title":"Proceedings of GenoPri","author":"DB Baker","year":"2017","unstructured":"Baker DB, Knoppers BM, Philips M, van Enckevort D, Kaufmann P, Lochmuller H, Taruscio D. Privacy-preserving linkage of geniomic and clinical datasets. In: Proceedings of GenoPri; 2017."},{"key":"998_CR19","doi-asserted-by":"publisher","unstructured":"Lochm\u00fcller H, Evans D, Farwell W, Finkel R, Goemans N. Lemus M de, et al. position statement: sharing of clinical research data in spinal muscular atrophy to accelerate research and improve outcomes for patients. J Neuromuscul Dis. 2018;5:131\u20133. \n                    https:\/\/doi.org\/10.3233\/JND-180325\n                    \n                  .","DOI":"10.3233\/JND-180325"},{"key":"998_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00415-013-7154-1","volume":"261","author":"CL Bladen","year":"2014","unstructured":"Bladen CL, Thompson R, Jackson JM, Garland C, Wegel C, Ambrosini A, et al. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J Neurol. 2014;261:152\u201363. \n                    https:\/\/doi.org\/10.1007\/s00415-013-7154-1\n                    \n                  .","journal-title":"J Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-0998-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-0998-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-0998-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T19:07:17Z","timestamp":1579547237000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-0998-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["998"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-0998-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Of the central ethics committee has been obtained (Ethics Committee of the University of Freiburg, Germany (EK 56\/18)).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JK received research funding and\/or compensation for presentations and consultancy from Avexis, Biogen, Ionis Pharmaceuticals, Novartis, and Roche. AP, SS, and SV received compensations for presentations and training activities from Biogen. MCW received research funding and\/or compensation for presentations and consultancy from Avexis, Biogen, Novartis, and Roche. US received compensation for presentations and consultancy from Avexis, Biogen, Ionis Pharmaceuticals, Novartis, and Roche. GB received compensation for presentations and consultancy from Biogen.\u00a0DS participated in sponsored workshops by Biogen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"18"}}